Literature DB >> 24270743

Comparison of contemporary troponin assays with the novel biomarkers, heart fatty acid binding protein and copeptin, for the early confirmation or exclusion of myocardial infarction in patients presenting to the emergency department with chest pain.

Paul Collinson1, David Gaze, Steve Goodacre.   

Abstract

OBJECTIVE: To examine the diagnostic accuracy of novel biomarkers of myocardial injury and troponin assays for diagnosis of myocardial infarction.
METHODS: 850 patients randomised to the point-of-care testing arm of the Randomised Assessment of Panel Assay of Cardiac markers (RATPAC) study in six emergency departments of low-risk patients presenting with chest pain were studied. Blood samples were obtained on admission and 90 min from admission. Myocardial infarction was defined by the universal definition of myocardial infarction. The following diagnostic strategies were compared by receiver operator characteristic curve analysis and comparison of area under the curve: individual marker values and the combination of presentation heart fatty acid binding protein (HFABP) and copeptin with troponin.
RESULTS: 68 patients had a final diagnosis of myocardial infarction. Admission samples were available from 838/1132 patients enrolled in the study. Areas under the curve were as follows (CIs in parentheses): cardiac troponin I (cTnI) Stratus CS 0.94 (0.90 to 0.98), cTnI Beckmann 0.92 (0.88 to 0.96), cTnI Siemens ultra 0.90 (0.85 to 0.95), cardiac troponin T high sensitivity 0.92 (0.88 to 0.96), HFABP 1 0.84 (0.77 to 0.90) copeptin 0.62 (0.57 to 0.68). HFABP and copeptin were diagnostically inferior to troponin. The combination of HFABP (at the 95th percentile) and troponin (at the 99th percentile) increased diagnostic sensitivity.
CONCLUSIONS: High-sensitivity cardiac troponin is the best single marker. Addition of HFABP to high-sensitivity troponin increased diagnostic sensitivity. Additional measurement of copeptin is not useful in the chest pain population.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24270743     DOI: 10.1136/heartjnl-2013-304716

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  8 in total

Review 1.  Copeptin as a Diagnostic and Prognostic Biomarker in Cardiovascular Diseases.

Authors:  Danni Mu; Jin Cheng; Ling Qiu; Xinqi Cheng
Journal:  Front Cardiovasc Med       Date:  2022-07-04

2.  Heart-type fatty acid-binding protein: an overlooked cardiac biomarker.

Authors:  Harsh Goel; Joshua Melot; Matthew D Krinock; Ashish Kumar; Sunil K Nadar; Gregory Y H Lip
Journal:  Ann Med       Date:  2020-08-04       Impact factor: 4.709

Review 3.  Copeptin testing in acute myocardial infarction: ready for routine use?

Authors:  Sebastian Johannes Reinstadler; Gert Klug; Hans-Josef Feistritzer; Bernhard Metzler; Johannes Mair
Journal:  Dis Markers       Date:  2015-04-16       Impact factor: 3.434

4.  Early discharge using single cardiac troponin and copeptin testing in patients with suspected acute coronary syndrome (ACS): a randomized, controlled clinical process study.

Authors:  Martin Möckel; Julia Searle; Christian Hamm; Anna Slagman; Stefan Blankenberg; Kurt Huber; Hugo Katus; Christoph Liebetrau; Christian Müller; Reinhold Muller; Philipp Peitsmeyer; Johannes von Recum; Milos Tajsic; Jörn O Vollert; Evangelos Giannitsis
Journal:  Eur Heart J       Date:  2014-04-30       Impact factor: 29.983

Review 5.  Copeptin-marker of acute myocardial infarction.

Authors:  Martin Möckel; Julia Searle
Journal:  Curr Atheroscler Rep       Date:  2014-07       Impact factor: 5.113

6.  Diagnostic accuracy of copeptin sensitivity and specificity in patients with suspected non-ST-elevation myocardial infarction with troponin I below the 99th centile at presentation.

Authors:  Jonathan Duchenne; Stéphanie Mestres; Nicolas Dublanchet; Nicolas Combaret; Geoffroy Marceau; Laurent Caumon; Laurent Dutoit; Sylvie Ughetto; Pascal Motreff; Vincent Sapin; Jeannot Schmidt
Journal:  BMJ Open       Date:  2014-03-24       Impact factor: 2.692

7.  The prognostic significance of heart-type fatty acid binding protein in patients with stable coronary heart disease.

Authors:  Sing-Kong Ho; Yen-Wen Wu; Wei-Kung Tseng; Hsin-Bang Leu; Wei-Hsian Yin; Tsung-Hsien Lin; Kuan-Cheng Chang; Ji-Hung Wang; Hung-I Yeh; Chau-Chung Wu; Jaw-Wen Chen
Journal:  Sci Rep       Date:  2018-09-26       Impact factor: 4.379

8.  Prognostic utility of heart-type fatty acid-binding protein in patients with stable coronary artery disease and impaired glucose metabolism: a cohort study.

Authors:  Hui-Wen Zhang; Jing-Lu Jin; Ye-Xuan Cao; Hui-Hui Liu; Yan Zhang; Yuan-Lin Guo; Na-Qiong Wu; Ying Gao; Rui-Xia Xu; Qi Hua; Yan-Fang Li; Chuan-Jue Cui; Geng Liu; Qian Dong; Jing Sun; Jian-Jun Li
Journal:  Cardiovasc Diabetol       Date:  2020-02-10       Impact factor: 9.951

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.